pioglitazone has been researched along with Chronic Kidney Failure in 9 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to test whether pioglitazone, a powerful insulin sensitizer, alters body fat distribution and adipokine secretion in these subjects and whether it is associated with improved insulin sensitivity." | 9.19 | Pioglitazone improves fat distribution, the adipokine profile and hepatic insulin sensitivity in non-diabetic end-stage renal disease subjects on maintenance dialysis: a randomized cross-over pilot study. ( Bertrand, PC; Bortolotti, M; Burnier, M; Gauthier, T; Halabi, G; Lê, KA; Mathieu, C; Tappy, L; Teta, D; Theumann, N; Tremblay, S; Zanchi, A, 2014) |
| " The aim of this study was to test whether pioglitazone, a powerful insulin sensitizer, alters body fat distribution and adipokine secretion in these subjects and whether it is associated with improved insulin sensitivity." | 5.19 | Pioglitazone improves fat distribution, the adipokine profile and hepatic insulin sensitivity in non-diabetic end-stage renal disease subjects on maintenance dialysis: a randomized cross-over pilot study. ( Bertrand, PC; Bortolotti, M; Burnier, M; Gauthier, T; Halabi, G; Lê, KA; Mathieu, C; Tappy, L; Teta, D; Theumann, N; Tremblay, S; Zanchi, A, 2014) |
| "To determine whether thiazolidinediones cause significant changes in intravascular volume, anemia, or chronic heart failure; to determine which thiazolidinedione, rosiglitazone or pioglitazone, has a greater propensity to cause these adverse effects; and to evaluate thiazolidinedione efficacy in patients with diabetes mellitus and end-stage renal disease who require hemodialysis." | 3.72 | Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. ( Allcock, NM; Manley, HJ, 2003) |
| "This study was performed to ascertain whether losartan combined with pioglitazone is superior to losartan alone in delaying the progression of chronic renal failure in patients with type 2 diabetic nephropathy." | 2.73 | Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy. ( Jin, HM; Pan, Y, 2007) |
| "Thus, diabetic nephropathy is currently the number one cause of end-stage renal disease in the Western world." | 2.43 | Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. ( Bakris, GL; Sarafidis, PA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zanchi, A | 1 |
| Tappy, L | 1 |
| Lê, KA | 1 |
| Bortolotti, M | 1 |
| Theumann, N | 1 |
| Halabi, G | 1 |
| Gauthier, T | 1 |
| Mathieu, C | 1 |
| Tremblay, S | 1 |
| Bertrand, PC | 1 |
| Burnier, M | 1 |
| Teta, D | 1 |
| Haidinger, M | 1 |
| Antlanger, M | 1 |
| Kopecky, C | 1 |
| Kovarik, JJ | 1 |
| Säemann, MD | 1 |
| Werzowa, J | 1 |
| Oei, E | 1 |
| Samad, N | 1 |
| Visser, A | 1 |
| Chowdhury, TA | 1 |
| Fan, SL | 1 |
| Chen, YH | 1 |
| Tarng, DC | 1 |
| Chen, HS | 1 |
| Manley, HJ | 1 |
| Allcock, NM | 1 |
| Sarafidis, PA | 1 |
| Bakris, GL | 1 |
| Jin, HM | 1 |
| Pan, Y | 1 |
| Schneider, CA | 1 |
| Ferrannini, E | 1 |
| Defronzo, R | 1 |
| Schernthaner, G | 1 |
| Yates, J | 1 |
| Erdmann, E | 1 |
| Nakamura, T | 1 |
| Ushiyama, C | 1 |
| Osada, S | 1 |
| Shimada, N | 1 |
| Ebihara, I | 1 |
| Koide, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Pioglitazone on Body Composition,Insulin Sensitivity and Protein Metabolism in ESRD Non Diabetic Individuals[NCT01253928] | Phase 4 | 16 participants (Anticipated) | Interventional | 2007-03-31 | Recruiting | ||
| The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy[NCT01175486] | Phase 4 | 200 participants (Anticipated) | Interventional | 2010-07-31 | Recruiting | ||
| PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy[NCT00174993] | Phase 3 | 4,373 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pioglitazone and Chronic Kidney Failure
| Article | Year |
|---|---|
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.
Topics: Albuminuria; Animals; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; E | 2006 |
5 trials available for pioglitazone and Chronic Kidney Failure
| Article | Year |
|---|---|
Pioglitazone improves fat distribution, the adipokine profile and hepatic insulin sensitivity in non-diabetic end-stage renal disease subjects on maintenance dialysis: a randomized cross-over pilot study.
Topics: Adipokines; Adipose Tissue; Adult; Body Composition; Cross-Over Studies; Double-Blind Method; Fastin | 2014 |
Renal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled Study.
Topics: Acarbose; Aged; Albumins; Albuminuria; Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Drug Th | 2016 |
Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Com | 2007 |
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.
Topics: Aged; Body Mass Index; Cardiovascular Diseases; Diabetic Angiopathies; Diabetic Nephropathies; Femal | 2008 |
Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes.
Topics: Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Hyperli | 2001 |
3 other studies available for pioglitazone and Chronic Kidney Failure
| Article | Year |
|---|---|
Post-transplantation diabetes mellitus: evaluation of treatment strategies.
Topics: Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glo | 2015 |
Use of continuous glucose monitoring in patients with diabetes on peritoneal dialysis: poor correlation with HbA1c and high incidence of hypoglycaemia.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 2016 |
Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis.
Topics: Aged; Aged, 80 and over; Blood Pressure; Comorbidity; Diabetes Complications; Diabetes Mellitus; Fem | 2003 |